Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyWellfleet Drug Testing Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentWellfleetPolicy GL-001

    Drug Test Payment Guideline

    Customize your policy alerts

    Sign up for wellfleet Policy GL-001 alerts

    Get alerted when Policy GL-001 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This payment guideline governs Wellfleet reimbursement for presumptive and definitive drug testing, including appropriate clinical indications, documentation, testing frequency, coding, and excluded uses. It applies to participating providers and applicable Wellfleet plan types.

    Policy Summary
    PayerWellfleet
    PolicyDrug Test Payment Guideline
    Policy CodePolicy GL-001
    Change TypeNo material change
    Effective DateAugust 1, 2022
    Next Review DateAugust 1, 2023
    Key ActionPerform definitive testing only when a presumptive drug class screen is positive and the definitive result will affect the member's treatment course.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    7 daysMinimum interval for random drug testing
    24 testsMinnesota medical-record-review threshold
    215 drugsPreferred multiplex screening reference
    1 per episode/eventFrequency limits for specified settings
    2 conditions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Requirements for definitive testing
    3 exclusionsExcluded coverage circumstances

    Covered and Non-Covered Drug Testing

    Covered Presumptive Screening Indications

    Presumptive drug class screening is covered when performed in any of the following circumstances:

    ANY of the following

    • During an episode of emergency room care1 per episode
    • During an episode of acute inpatient level of care
    • Upon admission into a substance abuse rehabilitation program1 screen on admission
    • During an initial pregnancy examination1 per initial examination
    • Prior to general anesthesia1 per procedure
    • For treatment of substance abuse

      May require medical record review.

    • Random drug testing of pregnant women with a known or documented history of drug abuse

      May require medical record review. See the definition of random drug testing.

    • Random drug testing to assure compliance with an opiate treatment agreement

      See the definition of random drug testing.

    Covered Definitive Testing Criteria

    Definitive drug testing is covered only when ALL of the following conditions are met:

    ALL of the following

    • A presumptive drug class screen has returned a positive result
    • The results of the definitive drug test will affect the course of the member's treatment

    Covered Medical-Condition Indications

    Wellfleet may cover drug testing for the following medical conditions when the testing is appropriate and treatment planning by the requesting provider is dependent upon the test results:

    ALL of the following

    • ANY of the following medical conditions or purposes

      • Altered mental status
      • A medical or psychiatric condition where drug toxicity may be a contributing factor
      • Fetal withdrawal syndrome
      • Possible exposure of the fetus to illicit drugs taken by the mother
      • Assessing and treating members with substance abuse disorders

    Confirmatory Testing Criteria

    Confirmatory drug testing by a second method, including G0480-G0483, is covered when the applicable result and treatment-planning requirements are met:

    ALL of the following

    • ANY of the following

      • The result of the screen is positive
      • The result is negative and the negative finding is inconsistent with the patient's medical history and/or treatment plan
    • The test results are necessary for treatment planning
    • The testing is requested by the ordering physician

      Written orders are required.

    Non-Covered Drug Testing

    Wellfleet does not cover drug testing in any of the following circumstances:

    ANY of the following

    • Testing ordered by third parties, such as schools, courts, or employers, or requested by a provider solely to meet a third party's requirements
    • Testing for routine (non-random) residential monitoring
    • Routine urinalysis for confirmation of specimen integrity

    Minnesota Opioid Testing Provision

    For Minnesota plans, effective January 1, 2022:

    ALL of the following

    • The member is enrolled in an inpatient or outpatient substance-use-disorder treatment program
    • The testing is for opioids by screening or urinalysis
    • Testing is ordered by a health care provider
    • Testing is performed by an accredited clinical laboratory
    • There is no annual or lifetime limit on the covered opioid screenings or urinalysis testing

      Wellfleet may conduct a medical records review if the member exceeds 24 screening or urinalysis tests in any 12-month period.

    Coding and Frequency Parameters

    CPT Drug Testing CodesCPT
    80305-80307Drug testing codes
    80320-80326Drug testing codes
    80345-80347Drug testing codes
    80349-80354Drug testing codes
    80356Drug testing code
    80358-80365Drug testing codes
    80368Drug testing code
    80371Drug testing code
    80373-80377Drug testing codes
    HCPCS Drug Testing CodesHCPCS
    G0431Drug testing code
    G0434Drug testing code
    G0477-G0483Drug testing and confirmation codes
    G6031Drug testing code
    G6045-G6047Drug testing codes
    G6049-G6054Drug testing codes
    G6056Drug testing code
    G6058Drug testing code
    G0659Drug testing code
    Proprietary Laboratory Drug Testing CodesCPT
    0007UDrug testing code
    0082UDrug testing code
    0143U-0150UDrug testing codes
    0227UDrug testing code
    Additional Listed Drug Testing CodesCPT
    82075Drug testing code
    83992Drug testing code
    Random Drug Testing Interval
    Testing typeRandom drug testing
    TimingOn different days of the week or different weeks of the month
    Minimum intervalNo more often than every seven (7) days
    Minnesota Opioid Testing Review Threshold
    Applies toEnrollees in inpatient or outpatient substance-use-disorder treatment under Minnesota plans
    Tests includedOpioid screening or urinalysis testing

    Provider Documentation and Testing Requirements

    Billing Rule

    Use presumptive screening only for appropriate indications

    Perform a presumptive drug class screen only when an enumerated clinical circumstance applies. Frequency limits apply where specified.

    • During an emergency-room episode — one per episode
    • During acute inpatient care
    • Upon admission to a substance-abuse rehabilitation program — one screen on admission
    • During an initial pregnancy examination — one per initial examination
    • Before general anesthesia — one per procedure
    • For substance-abuse treatment
    • Random testing of pregnant women with a known or documented history of drug abuse
    • Random testing to assure compliance with an opiate treatment agreement

    Drug Testing Terms

    Presumptive Drug Class Screening
    DefinitionAn initial assay for the presence of certain drug classes
    SpecimensUrine, blood, or other tissue
    PurposeIdentifies the presence of certain drug classes
    Definitive Drug Testing
    DefinitionAn initial assay for the presence of individual drugs within a class
    SpecimensUrine, blood, or other tissue
    Testing focusIndividual drugs within a drug class
    Policy Summary
    PayerWellfleet
    PolicyDrug Test Payment Guideline
    Policy CodePolicy GL-001
    Change TypeNo material change
    Effective DateAugust 1, 2022
    Next Review DateAugust 1, 2023
    Key ActionPerform definitive testing only when a presumptive drug class screen is positive and the definitive result will affect the member's treatment course.
    SourceLink
    On This Page
    Covered and Non-Covered Drug TestingCoding and Frequency ParametersProvider Documentation and Testing RequirementsDrug Testing Terms
  1. Assessing adherence to prescribed medications
  2. Treatment planning by the requesting provider is dependent upon the test results
  3. Medical-record-review thresholdMore than 24 screening or urinalysis tests in any 12-month period
    Emergency-Room Screening Frequency
    Test typePresumptive drug class screen
    Care settingEmergency-room episode
    Frequency limitOne per episode
    Rehabilitation Admission Screening Frequency
    Test typePresumptive drug class screen
    Care settingAdmission into a substance-abuse rehabilitation program
    Frequency limitOne screen on admission
    Initial Pregnancy Examination Screening Frequency
    Test typePresumptive drug class screen
    Clinical eventInitial pregnancy examination
    Frequency limitOne per initial examination
    Pre-General-Anesthesia Screening Frequency
    Test typePresumptive drug class screen
    Clinical eventPrior to general anesthesia
    Frequency limitOne per procedure
    Denial Risk

    Definitive testing requires positive screen and treatment impact

    Perform definitive testing only when a presumptive drug class screen has returned a positive result and the definitive result will affect the member’s treatment course. Definitive-test claims may be denied or pended when these conditions are not supported.

    • A presumptive drug class screen must be positive.
    • The definitive result must affect the member’s treatment course.
    Documentation Required

    Maintain supporting medical records

    Maintain all supporting documentation in the member’s record and make it available to Wellfleet upon request. Records must be legible and support the specific test, date of service, diagnosis coding, and service performed.

    • Include complete member identification and dates of service on every page.
    • Identify the physician or non-physician practitioner responsible for and providing the care.
    • Document the clinical reason or requirement for the specific drug test on the specified date.
    • Support the selected ICD-CM code and ensure the CPT or HCPCS code describes the service performed.
    Documentation Required

    Use specific written test orders

    Obtain a written order from the treating provider that identifies every drug or drug class to be tested. Open-ended orders, including “conduct additional testing as needed” or “custom profile,” will not be accepted.

    • Specify all drugs or drug classes included in the test.
    • Include the clinical indication and the date the specific test is to be performed.
    Documentation Required

    Retain order and result copies when providers differ

    When the testing provider is different from the ordering or referring provider, retain printed laboratory results and a printed copy of the specific order. The order must include the clinical indication and performance date.

    • Retain printed copies of laboratory results.
    • Retain the ordering or referring provider’s printed order for the specific drug test.
    • Ensure the order states the clinical indication and date performed.
    Denial Risk

    Limit full-panel and subsequent testing

    Use a full-panel screen only when appropriate for initial testing or when the member’s behavior suggests substances not identified in the original screen. Subsequent testing should generally be limited to substances identified initially unless the records support adding substances for a specific test date.

    • Document the justification for a full-panel screen.
    • Support any additional substances with medical records identifying a clinical reason for that specific test date.
    Prior Authorization

    Support confirmatory testing

    Confirmatory testing by a second method is indicated after a positive screen or when a negative result is inconsistent with the patient’s medical history or treatment plan. Coverage requires that the result be necessary for treatment planning, requested by the ordering physician, and supported by a written order.

    • Positive screening result; or
    • Negative screening result inconsistent with the patient’s medical history or treatment plan.
    • For drug confirmation by a second method, use codes G0480-G0483 when applicable.
    Documentation Required

    Respond to medical-record review

    Claims may be pended for information supporting the appropriateness of drug testing, and medical records are always required to support the appropriateness of a definitive drug test. Provide records that document the indication, test date, responsible provider, diagnosis-code support, and service performed.

    • Maintain records in the member’s file and make them available upon request.
    • Ensure every submitted page is legible and includes appropriate member identification.
    • Provide the written order identifying the drugs or drug classes tested.
    Billing Rule

    Use clinically appropriate testing frequency

    Perform testing at a frequency appropriate to clinical needs. For monitoring adherence to substance-abuse treatment, random testing is generally preferred over frequent scheduled testing.

    • Random testing means testing on different days of the week or different weeks of the month, no more often than every seven days.
    • Be prepared for medical-record review when Minnesota opioid screening or urinalysis exceeds 24 tests in any 12-month period for an enrollee in inpatient or outpatient substance-use-disorder treatment.
    Random Drug Testing
    DefinitionAdministration of a drug class screening test on different days of the week or different weeks of the month
    Timing requirementTesting occurs on varying days or weeks
    Minimum intervalNo more often than every seven (7) days